Regression of Fibrosis and Liver Related Complications in Patients with Hepatitis C Who Achieved Sustained Virological Response
Keywords:
HCV, SVR, Liver fibrosisAbstract
Background: Treatment with direct-acting antivirals (DAAs) eradicates hepatitis C virus from most patients. Information on regression of liver fibrosis and adverse outcomes is limited. Objective: The primary objective was to evaluate fibrosis changes in chronic hepatitis C (CHC) patients who achieved sustained virological response (SVR) with DAA-based therapy using transient elastography (TE). Secondary objectives were changes in non-invasive fibrosis scores; APRI and FIB-4, and liver and non-liver-related complications following SVR. Methods: This retro-prospective study was conducted at Rajavithi Hospital between June 2018 and June 2020. Consecutive CHC patients who achieved SVR with DAA were evaluated for TE, APRI, and FIB-4 under a standardized protocol at pre-treatment and follow-up periods of at least 12 months post-SVR. Fibrosis stages were categorized into F0/F1/F2/F3/F4. Fibrosis regression was defined as a reduction of the fibrosis stage after SVR. Results: Total of 104 patients were included with a mean follow-up of 20.5 (12-37) months. At pre-treatment, 74% had advanced fibrosis (F3-F4) with mean TE 18.8 kPa, FIB-4 3.4, and APRI 1.35. Following SVR, 61.5% had fibrosis regression, 35.6% had stationary fibrosis and 1.9% had fibrosis progression. Pre-treatment BMI≥25kg/m2 was significantly associated with less chance for fibrosis regression with an odd ratio of 2.34 (95%CI: 1.04, 5.25; p = .04), whereas HIV coinfection was significantly associated with a higher chance for fibrosis regression (p = .001). Two patients with de novo hepatocellular carcinoma were diagnosed at 14 and 39 months post-SVR (both had HCV genotype 3, obesity, and features of metabolic syndrome). There was no report of de novo hepatic decompensation and other significant liver and non-liver-related adverse events. Conclusion: Fibrosis regression was observed in most CHC patients after SVR and obesity was significantly associated with less chance to achieve fibrosis regression. Rare instances of de novo HCC were observed regardless of fibrosis status in which continuing surveillance should be recommended.
References
World Health Organization.Global Hepatitis Report 2017.Geneva: World Health Organization; 2017.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45-57.
Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55(3):403-8.
Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45(5):1290-7.
Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008;28(9):1102-10.
European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63(1):237-64.
D’Ambrosio R, Degasperi E, Lampertico P. Predicting epatocellular Carcinoma risk in patients with Chronic HCV infection and a sustained virological response to directacting antivirals. J Hepatocell Carcinoma 2021;8:713-39.
Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with Chronic Hepatitis C: A Systematic Review and meta-analysis. Clin Gastroenterol Hepatol 2018;16(1):27-38.e4
Shiha G, Soliman R, Mikhail N, Ibrahim A, Serwah AH, Khattab M. Changes in hepatic fibrosis stages after achieving SVR following direct-acting anti-viral treatment: a prospective study. GastroHep 2020;2(1):39-48.
American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, management and treating hepatitis C. [internet] 2020 [cited 2021 Jan 15] Available from: http://www.hcvguidelines.org/.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020;73(5):1170-218.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128(2):343-50.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46(1):32-6.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38(2):518-26.
Lledo GM, Carrasco I, Benitez-Gutierrez LM, Arias A, Royuela A, Requena S, et al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS 2018;32(16):2347-52.
Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, et al. Long-term changes in liver elasticity in hepatitis C virusinfected patients with sustained virologic response after treatment with direct-acting antivirals. United European Gastroenterol J 2018;6(8):1188-98.
Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, et al. Disease progression in patients with Hepatitis C Virus infection treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2020;18(11):2554-63.
D’Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 2022;76(2):302-10.
Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol 2018;69(5):1088-98.
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology 2017;152(1):142-56.
Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver Int 2017;37(9):1389-96.
Ortiz V, Berenguer M, Rayón JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97(9):2408-14.
Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52(1 Suppl):1035-40.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Department of Medical Services, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์
